Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Pancreatic Neoplasms 11Colorectal Neoplasms 10Neoplasm Metastasis 6Rhabdomyosarcoma 3Neuroblastoma 3Lung Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Sarcoma 2Rectal Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Colonic Neoplasms 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Refractory Solid Tumors 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Medulloblastoma 1Malignant mesenchymal tumor 1Intestinal Neoplasms 1Gastrointestinal Neoplasms 1

Interventions

X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Magnetic Resonance Spectroscopy 4Vincristine 3Specimen Handling 3Irinotecan 3Cyclophosphamide 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2larotrectinib 2ivosidenib 2ensartinib 2Temozolomide 2Radiotherapy 2temsirolimus 1tazemetostat 1talazoparib 1palbociclib 1olaparib 1liposomal doxorubicin 1irinotecan sucrosofate 1fludarabine phosphate 1fludarabine 1erdafitinib 1cabozantinib 1atezolizumab 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Rhabdomyosarcoma × Irinotecan × 30 days × Clear all
NCT04796012 2026-06-02

VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
23 enrolled
Sarcoma

Rhabdomyosarcoma

NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

NCT00077285 2026-05-22

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
65 enrolled
Sarcoma

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡